Bacterial Sialadenitis is an infection of one or more of the salivary glands, mainly caused by bacteria. It results in swelling of the salivary glands and can cause pain. Treatment involves use of antibiotics and pain relievers to get rid of the bacterial infection and reduce swelling and discomfort.
Market key trends:
One of the key trend in the bacterial sialadenitis market is growing adoption of combination therapies. Combination therapies involve use of two or more drugs that work by different mechanisms. For bacterial sialadenitis, combinations of antibiotics along with corticosteroids are being increasingly used. The antibiotics help clear the bacterial infection while corticosteroids help reduce inflammation and swelling of the salivary glands faster. Combination therapies provide faster relief and have higher success rates, thereby driving their increased adoption.
The global bacterial sialadenitis market is dominated by the infectious subsegment. Approximately 78% of the total market share is occupied by the infectious subsegment, as bacterial sialadenitis is mainly caused due to bacterial infections of the salivary glands. The main bacterial culprits causing this condition include Staphylococcus aureus and Streptococcus pneumoniae.
The global Bacterial Sialadenitis Market Share is estimated to be valued at US$ 1.90 Bn in 2023 and is expected to exhibit a CAGR of 5.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global bacterial sialadenitis market is expected to witness high growth, exhibiting CAGR of 5.6% over the forecast period, due to increasing prevalence of infectious diseases.
The North American region is expected to dominate the global bacterial sialadenitis market owing to the rising cases of infectious disorders in this region. Europe holds the second largest market share due to increasing government initiatives to spread awareness about infectious diseases.
Key players operating in the bacterial sialadenitis market are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc, Novartis AG, Sanofi S.A., Johnson & Johnson, Abbott Laboratories, Eli Lilly and Company, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Roche Holding AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Allergan plc. These players are focused on developing innovative drug formulations to treat bacterial sialadenitis.